Autor: Prof. Dr. med. Martin Bornhäuser, Universitätsklinikum Carl Gustav Carus, Dresden
Quellenangabe: Deutsches MDS-Forum - Dresden 2006
Stand: 27.11.2006
Anderson JE.
Bone marrow transplantation for myelodysplasia.
Blood Rev 2000;14:63-77. PM:10913969
[Medline]
Bornhäuser M, Storer B, Slattery JT.
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Blood 2003;102:820-826. PM:12676781
[Medline]
Castro-Malaspina H, Harris RE, Gajewski J.
Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.
Blood 2002;99:1943-1951. PM:11877264
[Medline]
Cutler CS, Lee SJ, Greenberg P.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
Blood 2004;104:579-585. PM:15039286
[Medline]
Deeg HJ, Shulman HM, Anderson JE.
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.
Blood 2000;95:1188-1194. PM:10666189
[Medline]
Deeg HJ, Storer B, Slattery JT.
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.
Blood 2002;100:1201-1207. PM:12149198
[Medline]
Deeg HJ, Maris MB, Scott BL, Warren EH.
Optimization of allogeneic transplant conditioning: not the time for dogma.
Leukemia 2006;20:1701-1705. PM:16888618
[Medline]
Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A.
EBMT activity survey 2004 and changes in disease indication over the past 15 years.
Bone Marrow Transplant 2006;37:1069-1085. PM:16757972
[Medline]
Guardiola P, Runde V, Bacigalupo A.
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes.
Blood 2002;99:4370-4378. PM:12036864
[Medline]
Lim ZY, Ho AY, Ingram W.
Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes.
Br J Haematol 2006;135:201-209. PM:16939494
[Medline]
Martino R, Iacobelli S, Brand R.
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
Blood. 2006;108:836-846. PM:16597592
[Medline]
Scott BL, Sandmaier BM, Storer B.
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.
Leukemia 2006;20:128-135. PM:16270037
[Medline]
Sierra J, Perez WS, Rozman C.
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.
Blood 2002;100:1997-2004. PM:12200358
[Medline]